Researchers from the Stern Stroke Center at Montefiore Medical Center published trial results this week showing that stroke survivors were twice as likely to take anticoagulants when using an artificial intelligence platform compared to patients receiving standard therapies.
The AI platform, AiCure, features software algorithms on smartphones that confirm patient identify, medication and drug ingestion. Patients receive automated reminders and precise dosing instructions and healthcare workers can review data in real-time.
Get the full story at our sister site, Drug Delivery Business News.
The post Patients twice as likely to take anticoagulants with artificial intelligence platform appeared first on MassDevice.
from MassDevice http://ift.tt/2ogzfLs
Cap comentari:
Publica un comentari a l'entrada